Eli Lilly and Company $LLY Stock Holdings Boosted by Bridgeway Capital Management LLC

Key Points

• Bridgeway Capital Management LLC increased its stake in Eli Lilly and Company by 1.2%, acquiring an additional 355 shares, bringing its total holdings to 30,959 shares valued at approximately $25.57 million.
• Eli Lilly reported strong quarterly earnings of $6.31 per share, exceeding analyst expectations and achieving a year-over-year revenue increase of 37.6% to $15.56 billion.
• The company announced a quarterly dividend of $1.50, representing an annualized payout of $6.00 and a yield of 0.8%, set to be paid on September 10th.

Bridgeway Capital Management LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,959 shares of the company's stock after buying an additional 355 shares during the period. Eli Lilly and Company makes up approximately 0.6% of Bridgeway Capital Management LLC's investment portfolio, making the stock its 8th largest position. Bridgeway Capital Management LLC's holdings in Eli Lilly and Company were worth $25,569,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. WestEnd Advisors LLC boosted its stake in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $27,000. Citizens National Bank Trust Department boosted its stake in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $40,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $43,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 2.2%

Eli Lilly and Company stock traded down $16.56 during mid-day trading on Friday, hitting $726.35. 3,953,474 shares of the stock were exchanged, compared to its average volume of 5,282,453. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $942.35. The firm's fifty day simple moving average is $743.84 and its two-hundred day simple moving average is $781.81. The stock has a market capitalization of $687.46 billion, a price-to-earnings ratio of 47.47, a PEG ratio of 1.03 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is currently 39.22%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Leerink Partners reiterated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, UBS Group dropped their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $950.17.

Insider Buying and Selling

In other news, EVP Daniel Skovronsky acquired 1,000 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 over the last ninety days. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.